CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Tr...

Long-term data from the pivotal HOPE-B study show a one-time infusion of HEMGENIX generated elevated and sustained mean factor IX levels and reduc...

Related Keywords

United States ,Michigan ,American ,Etanjalie Ayala ,Maria Tortoreto ,American Society Of Hematology ,Twitter ,Drug Administration ,Operations Communications ,Behring Pharmacovigilance Department ,University Of Michigan ,Wrd Communications ,American Society ,Steven Pipe ,Month Extension ,About Hemophilia ,Annual Bleeding Rate ,Safety Information ,Pharmacovigilance Department ,